Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.32 |
| ▸ | USP8 | P40818 | 1/20 | 0.30 |
| ▸ | USP7 | Q93009 | 1/20 | 0.30 |
| ▸ | USP47 | Q96K76 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30716074 | 0.86 | PTPN1 (0.34) | PTPN1CA1CA2CA7CA9 | |
| SCHEMBL7432077 | 0.86 | PTPN1 (0.34) | PTPN1CA1CA2CA7CA9 | |
| SCHEMBL10560302 | 0.81 | PTPN1 (0.43) | PTPN1CA1CA2CA7CA9 | |
| SCHEMBL7442079 | 0.79 | CDC25B (0.41) | PTPN1ACHE | |
| SCHEMBL9457098 | 0.70 | PTPN1 (0.38) | PTPN1CA1CA2CA7CA9 | |
| SCHEMBL8078213 | 0.70 | PTPN1 (0.40) | PTPN1CA1CA2CA7CA9 | |
| SCHEMBL6653492 | 0.70 | PTPN1 (0.33) | PTPN1CA1CA2CA7CA9 | |
| SCHEMBL28903176 | 0.69 | S100A4 (0.42) | CA1CA2CA7CA9ACHE | |
| SCHEMBL29651997 | 0.69 | S100A4 (0.42) | CA1CA2CA7CA9ACHE | |
| SCHEMBL30423643 | 0.69 | BACE1 (0.49) | PTPN1PARK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0092385-B1 | HYDANTOIN DERIVATIVES FOR USE IN INHIBITING ALDOSE REDUCTASE ACTIVITY, COMPOSITIONS THEREFOR AND PROCESS FOR PREPARING SPIRO-FLUOREN COMPOUNDS | ALCON LABORATORIES, INC. (US) | 1991-06-12 | — | — | EP | disclosed |
| US-4540700-A | Treatment of diabetic complications with certain spiro-imidazolidine-diones | ALCON LABORATORIES, INC. (US) | 1985-09-10 | — | — | US | disclosed |
| US-4438272-A | COMPLICATIONS OF DIABETES | ALCON LABORATORIES, INC. (US) | 1984-03-20 | — | — | US | disclosed |
| US-4436745-A | TETRACYCLIC SPIROHYDANTOINS | ALCON LABORATORIES, INC. (US) | 1984-03-13 | — | — | US | disclosed |
| WO-1983003543-A1 | METHOD OF INHIBITING ALDOSE REDUCTASE ACTIVITY, COMPOSITIONS THEREFOR AND PROCESS FOR PREPARING SPIRO-FLUOROFLUOREN AND SPIRO-DIFLUOROFLUOREN COMPOUNDS | ALCON LAB INC (US) | 1983-10-27 | — | — | WO | disclosed |
| EP-0092385-A2 | Hydantoin derivatives for use in inhibiting aldose reductase activity, compositions therefor and process for preparing spiro-fluoren compounds | ALCON LABORATORIES, INC. (US) | 1983-10-26 | — | — | EP | disclosed |